Pharmacoeconomic validation to chronic HBV-infection ethiotropic therapy prescription in Republic of Sakha (Yakutia)

• Sleptsova S.S.
• Malogulova I.Sh.
• Andreev M.N.
• Efimov A.E.
• Kuz'mina A.A.

Abstract

Viral hepatitis B is important problem for healthcare systems around the world. In 2013, economic dam­age for Russian Federation from acute HBV-infection is 349 049.8 thousand RUB, chronic HBV-infection - 694 220.9 thousand RUB. In RepubLic of Sakha (Yakutia) we can notice high prevaLence of HBV-infection. Authors presenting resuLts of pharmacoeconomic vaLidation to chronic HBV-infection ethiotropic therapy by nucLeoside anaLogues with method of cost-effective efficiency and the state budget economy modeLLing. Safety and efficiency nucLeoside anaLogues using (entecavir, tenofovir) confirmed in randomized controLLed triaLs. In current articLe TerritoraL department of Rospotrebnadzor officiaL statistics had been used. ResuLting this articLe, antiviraL therapy using wouLd be decrease number of patients with decompensated Liver cirrhosis at 6 times (from 3.7 to 0.6%), hepatoceLLuLar carcinoma at 3 times (from 2.3 to 0.8%), and decrease mortaLity at 2 times (from 22 to 10%). In addition, nucLeoside anaLogues treatment wouLd prevent manufacturaL Losses reLated with GDP underproduction caused by retirement due to disabiLity or death - totaL 908 mLn. RUB per year in RepubLic of Sakha (Yakutia).

Keywords:viral hepatitis, hepatitis B virus, nucleoside analogues, cirrhosis of the liver, primary liver cancer, pharmacoeconomic analysis

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)